There is currently increasing interest in SNP mutations in EGFR, given that they could affect the efficacy of EGFR tyrosine kinase inhibitor (TKI) treatment in various cancers [44], colorectal cancer [39], non-small cell lung cancer [45], GC [46]–[49]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.